These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35491532)

  • 21. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
    Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
    J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
    N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    Feng C; Wu M; Chen Z; Yu X; Nie Z; Zhao Y; Bao B
    Int Urol Nephrol; 2019 Apr; 51(4):655-669. PubMed ID: 30830656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
    Sen T; Koshino A; Neal B; Bijlsma MJ; Arnott C; Li J; Hansen MK; Ix JH; Heerspink HJL
    Diabetes Obes Metab; 2022 Oct; 24(10):1950-1956. PubMed ID: 35635326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
    Heerspink HJ; Desai M; Jardine M; Balis D; Meininger G; Perkovic V
    J Am Soc Nephrol; 2017 Jan; 28(1):368-375. PubMed ID: 27539604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan.
    Wada T; Mori-Anai K; Takahashi A; Matsui T; Inagaki M; Iida M; Maruyama K; Tsuda H
    J Diabetes Investig; 2022 Dec; 13(12):1981-1989. PubMed ID: 35861630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study).
    Kato S; Kuwatsuka Y; Ando M; Tatematsu Y; Nishibori N; Maruyama S
    BMC Nephrol; 2023 Aug; 24(1):228. PubMed ID: 37537531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
    Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
    Seidu S; Kunutsor SK; Cos X; Gillani S; Khunti K;
    Prim Care Diabetes; 2018 Jun; 12(3):265-283. PubMed ID: 29482993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
    Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
    Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors for the development of microalbuminuria and interaction with renal function.
    Chatzikyrkou C; Menne J; Izzo J; Viberti G; Rabelink T; Ruilope LM; Rump C; Mertens PR; Haller H
    J Hypertens; 2017 Dec; 35(12):2501-2509. PubMed ID: 29035939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial.
    Doi Y; Hamano T; Yamaguchi S; Sakaguchi Y; Kaimori JY; Isaka Y
    Diabetes Obes Metab; 2023 Oct; 25(10):2944-2953. PubMed ID: 37385955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.
    Oshima M; Neal B; Toyama T; Ohkuma T; Li Q; de Zeeuw D; Heerspink HJL; Mahaffey KW; Fulcher G; Canovatchel W; Matthews DR; Perkovic V
    J Am Soc Nephrol; 2020 Oct; 31(10):2446-2456. PubMed ID: 32694216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
    Heerspink HJL; Oshima M; Zhang H; Li J; Agarwal R; Capuano G; Charytan DM; Craig J; de Zeeuw D; Di Tanna GL; Levin A; Neal B; Perkovic V; Wheeler DC; Yavin Y; Jardine MJ
    Am J Kidney Dis; 2022 Feb; 79(2):244-256.e1. PubMed ID: 34029680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.